


Product Name	: Bilastine
Synonyms	: Bilastine trade name Bilaxten
Cat No.	: M18206
CAS Number	: 202189-78-4
Molecular Formula	: C ₂₈ H ₃₇ N ₃ O ₃
Formula Weight	: 463.62
Chemical Name	: 2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoic acid
Description	Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives). It exerts its effect as a selective histamine H₁ receptor antagonist, and has a potency similar to cetirizine and is superior to fexofenadine. It was developed in Spain by FAES Farma. Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjunctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.
Pathway	: Endocrinology/Hormones
Target	: 5-HT Receptor
Receptor	: H ₁ receptor
Solubility	: DMSO : ≥ 49.3 mg/mL; 106.34 mM
SMILES	: <chem>CCOCCn1c(nc2ccccc12)C1CCN(CCC2CCC(CC2)C(C)(C)C(=O)O)CC1</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:



1. Wolthers OD. Bilastine: a new nonsedating oral H₁ antihistamine for treatment of allergic rhinoconjunctivitis and urticaria. Biomed Res Int. 2013;2013:626837.